NITI Aayog organises workshop on ‘Strengthening Mental Health Services and Care in India’

The workshop was conducted as a part of the NITI–State workshop series

European Commission approves Pfizer’s Talzenna in combination with Xtandi for treatment of metastatic castration-resistant prostate cancer

TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union

Jiangsu Vcare files NDA for Vicagrel Capsules with USFDA

Merck announces Phase 3 trial initiations for 4 Investigational Candidates from hematology and oncology pipeline

Comprehensive clinical development programs being initiated for each investigational candidate

Hyderabad to host 66th All India Congress of Obstetrics and Gynaecology 2024

The congress aims at emphasizing on the most recent trends, advancements in the field of Obstetrics & Gynaecology

Palatin completes sale of Vyleesi to Cosette Pharmaceuticals for up to $171 mn

Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)

Sun Pharma to acquire 16.7% stake in Lyndra Therapeutics for $30 mn

According to Sun Pharma, the purpose of the strategic investment is to obtain access to the technology for certain compounds and territories while also fostering the development of novel pharmaceutical delivery systems.

Eugia Pharma Specialities receives USFDA final approval for Posaconazole Injection

The product is expected to be launched in December 2023

Lyndra Therapeutics raises US$101 million in Series E funding

Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners

Zydus receives USFDA approval USFDA to initiate Phase II clinical trial of ZYIL1 for Parkinson's disease

Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation